12 Month Price Forecast For AVBP
Distance to AVBP Price Forecasts
AVBP Price Momentum
🤔 Considering Arrivent (AVBP)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 3:01 AM UTC
AVBP Analyst Ratings & Price Targets
Based on our analysis of 5 Wall Street analysts, AVBP has a consensus that is bullish. The median price target is $38.00, with forecasts ranging from $36.00 to $41.00. Currently, there are 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With AVBP currently trading at $26.63, the median price forecast suggests a 42.7% upside. The most optimistic forecast comes from at , projecting a 54.0% upside, while Robert Burns at HC Wainwright & Co. provides the most conservative target, suggesting a 35.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AVBP Analyst Consensus
AVBP Price Target Range
Latest AVBP Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AVBP.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 15, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $36.00 |
| Sep 11, 2024 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $36.00 |
| Sep 10, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $36.00 |
| Sep 10, 2024 | Oppenheimer | Jeff Jones | Outperform | Reiterates | $39.00 |
| Sep 10, 2024 | Goldman Sachs | Corinne Johnson | Buy | Maintains | $38.00 |
| Aug 16, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $30.00 |
| Aug 15, 2024 | Oppenheimer | Jeff Jones | Outperform | Reiterates | $35.00 |
| Jun 6, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $25.00 |
| May 9, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $25.00 |
| Apr 30, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Initiates | $25.00 |
| Feb 20, 2024 | Goldman Sachs | Corinne Johnson | Buy | Initiates | $27.00 |
| Feb 20, 2024 | Citigroup | Yigal Nochomovitz | Buy | Initiates | $30.00 |
| Feb 20, 2024 | Jefferies | Kelly Shi | Buy | Initiates | $35.00 |
Stocks Similar to ARRIVENT BIOPHARMA INC
The following stocks are similar to Arrivent based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ARRIVENT BIOPHARMA INC (AVBP) Financial Data
ARRIVENT BIOPHARMA INC has a market capitalization of $900.39M with a P/E ratio of -12.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -31.0%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
ARRIVENT BIOPHARMA INC (AVBP) Company Overview
About ARRIVENT BIOPHARMA INC
Develops targeted cancer therapies for unmet medical needs.
The company focuses on the clinical development and commercialization of innovative biopharmaceuticals aimed at treating various cancers, particularly through targeted therapies. Its revenue model primarily involves partnerships and collaborations with other pharmaceutical companies, as well as potential future sales of its proprietary drugs, such as Furmonertinib, once they receive regulatory approval.
ArriVent BioPharma is a clinical-stage company founded in 2021 and headquartered in Newtown Square, Pennsylvania. It is actively engaged in multiple clinical trials for its lead product, Furmonertinib, which targets specific mutations in non-small cell lung cancer. The company has established strategic collaborations to enhance its drug development capabilities.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
40
CEO
Dr. Zhengbin Yao Ph.D.
Country
United States
IPO Year
2014
Website
www.arrivent.comARRIVENT BIOPHARMA INC (AVBP) Latest News & Analysis
ArriVent BioPharma has secured an exclusive license to develop and commercialize MRG007, an antibody-drug conjugate targeting GI cancers, outside Greater China.
The exclusive licensing deal for MRG007 expands ArriVent's portfolio and market potential in GI cancers, potentially enhancing revenue prospects and attracting investor interest.
From 2001 to 2023, biotech and pharmaceutical companies accounted for about 24% of all initial public offerings (IPOs).
Biotech and pharmaceutical IPOs represent a significant portion of the market, indicating potential growth and investment opportunities in the sector, influencing portfolio decisions.
ArriVent BioPharma reported positive interim Phase 1b data for firmonertinib in NSCLC with 81.8% overall response rate. A webinar on these results is scheduled for September 9, 2024.
Positive Phase 1b data for firmonertinib in treating NSCLC with EGFR mutations suggests strong efficacy, potentially boosting ArriVent's stock value and attracting investor interest.
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 27.26%: Read This Before Placing a Bet
5 months agoAnalysts' price targets for ArriVent BioPharma (AVBP) suggest a 27.3% upside, supported by a consensus increase in earnings estimates.
Analysts' bullish price targets suggest significant upside for ArriVent BioPharma, indicating potential growth and increased investor interest despite mixed effectiveness of such metrics.
Firmonertinib, a once-daily treatment for EGFR PACC mutant non-small cell lung cancer, will present clinical proof-of-concept data at the 2024 World Conference on Lung Cancer.
Positive data on firmonertinib for NSCLC could boost the drug's market potential, impacting the company's stock price and attracting interest from investors in oncology.
Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma
5 months agoAarvik Therapeutics announced that ArriVent BioPharma has exercised its option to exclusively license a collaboration program, indicating a strategic partnership in biotechnology.
Aarvik's collaboration with ArriVent enhances its biotech prospects, potentially increasing revenue and market value, signaling confidence in its therapeutic developments.
Frequently Asked Questions About AVBP Stock
What is ARRIVENT BIOPHARMA INC's (AVBP) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, ARRIVENT BIOPHARMA INC (AVBP) has a median price target of $38.00. The highest price target is $41.00 and the lowest is $36.00.
Is AVBP stock a good investment in 2025?
According to current analyst ratings, AVBP has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $26.63. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for AVBP stock?
Wall Street analysts predict AVBP stock could reach $38.00 in the next 12 months. This represents a 42.7% increase from the current price of $26.63. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is ARRIVENT BIOPHARMA INC's business model?
The company focuses on the clinical development and commercialization of innovative biopharmaceuticals aimed at treating various cancers, particularly through targeted therapies. Its revenue model primarily involves partnerships and collaborations with other pharmaceutical companies, as well as potential future sales of its proprietary drugs, such as Furmonertinib, once they receive regulatory approval.
What is the highest forecasted price for AVBP ARRIVENT BIOPHARMA INC?
The highest price target for AVBP is $41.00 from at , which represents a 54.0% increase from the current price of $26.63.
What is the lowest forecasted price for AVBP ARRIVENT BIOPHARMA INC?
The lowest price target for AVBP is $36.00 from Robert Burns at HC Wainwright & Co., which represents a 35.2% increase from the current price of $26.63.
What is the overall AVBP consensus from analysts for ARRIVENT BIOPHARMA INC?
The overall analyst consensus for AVBP is bullish. Out of 5 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $38.00.
How accurate are AVBP stock price projections?
Stock price projections, including those for ARRIVENT BIOPHARMA INC, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
